Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer Mar 3, 2021
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM Feb 17, 2021
Kintara Therapeutics Announces Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update Feb 12, 2021
Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer Feb 3, 2021
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial Jan 13, 2021
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial Jan 6, 2021
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference Jan 5, 2021
Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study Nov 19, 2020
